CHADDS FORD, Pa., June 5 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals announced today that it will present at the Goldman Sachs 30th Annual Healthcare Conference on Wednesday, June 10, 2009 at 4:30 pm Eastern Time. Dave Holveck, President and Chief Executive Officer of Endo, will review the company's products and development programs.
The presentation will be webcast live and can be accessed from Endo's website at http://www.endo.com/ under the investors section.
About Endo
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; Percocet(R) and Percodan(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and Voltaren(R)Gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees. Voltaren(R)Gel is owned and licensed by Novartis AG; SANCTURA(R) and its XR version for treatment of overactive bladder, VANTAS(R) for the palliative treatment of advanced prostate cancer, and SUPPRELIN(R) LA for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, endocrinology and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at http://www.endo.com/.
Endo Pharmaceuticals
CONTACT: Media/Investors, Blaine Davis, +1-610-459-7158, or Media, Kevin
Wiggins, +1-610-459-7281, both of Endo Pharmaceuticals
Web Site: http://www.endo.com/
